



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Racotumomab

<b>Cat. No.:</b>	HY-P99254
<b>CAS No.:</b>	946832-34-4
<b>Target:</b>	Others
<b>Pathway:</b>	Others
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	<p>Racotumomab (Anti-Human NGcGM3 Recombinant Antibody) is an anti-idiotypic monoclonal antibody (MAb). Racotumomab reacts to Neu-glycolyl (NeuGc)-containing gangliosides, sulfatides, and other antigens expressed in tumors. Racotumomab is an active anticancer agent for lung cancer<sup>[1][2][3]</sup>.</p>									
<b>In Vitro</b>	<p>Racotumomab induces a specific humoral and cellular immune response against the NeuGcGM3 ganglioside present in tumor cells, stimulating the cell death<sup>[4]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>									
<b>In Vivo</b>	<p>Racotumomab (50 µg/dose, i.p.) together with Keyhole limpet hemocyanin (KLH) inhibits tumor growth in F3II cell (s.c.) mammary tumor mice model<sup>[2]</sup>. Racotumomab (50 µg/dose, s.c.) together with Pemetrexed (100 mg/kg) is highly effective against lung nodules in 3LL cell (s.c.) mice xenograft<sup>[3]</sup>. Racotumomab (50-200 µg/dose, s.c.) shows no significant antitumor effect in 3LL cell (s.c.) mice xenograft<sup>[3]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>3LL cell (s.c.) mice xenograft<sup>[3]</sup></td> </tr> <tr> <td>Dosage:</td> <td>50 µg/dose, together with Pemetrexed (100 mg/kg)</td> </tr> <tr> <td>Administration:</td> <td>Subcutaneous injection (s.c.)</td> </tr> <tr> <td>Result:</td> <td>Reduced lung nodules.</td> </tr> </table>		Animal Model:	3LL cell (s.c.) mice xenograft <sup>[3]</sup>	Dosage:	50 µg/dose, together with Pemetrexed (100 mg/kg)	Administration:	Subcutaneous injection (s.c.)	Result:	Reduced lung nodules.
Animal Model:	3LL cell (s.c.) mice xenograft <sup>[3]</sup>									
Dosage:	50 µg/dose, together with Pemetrexed (100 mg/kg)									
Administration:	Subcutaneous injection (s.c.)									
Result:	Reduced lung nodules.									

### REFERENCES

- [1]. Vázquez AM, et al. Racotumomab: an anti-idiotypic vaccine related to N-glycolyl-containing gangliosides - preclinical and clinical data. *Front Oncol.* 2012 Oct 23;2:150.
- [2]. Gajdosik Z. Racotumomab - a novel anti-idiotypic monoclonal antibody vaccine for the treatment of cancer. *Drugs Today (Barc).* 2014 Apr;50(4):301-7.
- [3]. Segatori VI, et al. Preclinical evaluation of racotumomab, an anti-idiotypic monoclonal antibody to N-glycolyl-containing gangliosides, with or without chemotherapy in a mouse model of non-small cell lung cancer. *Front Oncol.* 2012 Nov 8;2:160.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA